Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 13/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | BCR | P11274 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13241246 | 0.87 | ABL1 (0.66) | SYKABL1PDGFRBBCRSRC | |
| SCHEMBL2991040 | 0.86 | ABL1 (0.66) | SYKABL1PDGFRBBCRSRC | |
| SCHEMBL2994662 | 0.84 | ABL1 (0.54) | SYKABL1PDGFRBBCRSRC | |
| SCHEMBL2992321 | 0.84 | ABL1 (0.73) | SYKABL1PDGFRBBCRSRC | |
| SCHEMBL3858318 | 0.82 | ABL1 (0.84) | SYKABL1PDGFRBBCRSRC | |
| SCHEMBL16802310 | 0.82 | ABL1 (0.68) | SYKABL1PDGFRBBCRSRC | |
| SCHEMBL14949947 | 0.82 | ABL1 (0.61) | SYKABL1PDGFRBBCRSRC | |
| SCHEMBL2990662 | 0.82 | ABL1 (0.70) | SYKABL1PDGFRBBCRSRC | |
| SCHEMBL2983673 | 0.81 | ABL1 (0.60) | SYKABL1PDGFRBBCRSRC | |
| SCHEMBL2988415 | 0.80 | ABL1 (0.67) | SYKABL1PDGFRBBCRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259329-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA CELLULAR THERAPIES INC (US) | 2015-09-17 | — | — | US | disclosed |
| US-9056837-B2 | Heterocycle compounds and uses thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130123269-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8367686-B2 | Heterocycle compounds and uses thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100173924-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES INC. | 2010-07-08 | — | — | US | disclosed |
| EP-2166858-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | Intra-Cellular Therapies, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008153959-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259329-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | SYK 688/4885ABL1 481/4885PDGFRB 914/4885 |
| US-20100173924-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | SYK 627/4885ABL1 456/4885PDGFRB 935/4885 |
| US-20130123269-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | SYK 688/4885ABL1 481/4885PDGFRB 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.